Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib
暂无分享,去创建一个
H. Kantarjian | T. Smith | F. Giles | O. Ottmann | H. Schran | O. Yin | C. Tanaka | O. Yin | V. Sethuraman | K. Grouss | L. Galitz | O. Ottmann | Thomas C. Smith | X. Wang | Xin Wang | O G Ottmann | O Q P Yin | O. Yin | Lawrence A Galitz
[1] A. Stead,et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Richard Pazdur,et al. Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib , 2008, Clinical Cancer Research.
[3] S. Yamashita,et al. Rate-Limiting Steps of Oral Absorption for Poorly Water-Soluble Drugs in Dogs; Prediction from a Miniscale Dissolution Test and a Physiologically-Based Computer Simulation , 2008, Pharmaceutical Research.
[4] H. Kantarjian,et al. Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML) , 2008 .
[5] J. Radich,et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. , 2008, Blood.
[6] R. Larson,et al. Nilotinib in Patients (pts) with Philadelphia Chromosome-Positive (Ph+) Chronic Myelogenous Leukemia in Blast Crisis (CML-BC) Who Are Resistant or Intolerant to Imatinib. , 2007 .
[7] K. Bhalla,et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. , 2007, Blood.
[8] Hans Lennernäs,et al. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. , 2007, Current drug metabolism.
[9] Philippe Broët,et al. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. , 2007, Blood.
[10] H. Kantarjian,et al. Outcome of patients with Philadelphia chromosome‐positive chronic myelogenous leukemia post‐imatinib mesylate failure , 2007, Cancer.
[11] Doriano Fabbro,et al. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia , 2006, Acta crystallographica. Section D, Biological crystallography.
[12] K. Bhalla,et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.
[13] J. Mestan,et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL , 2006, British Journal of Cancer.
[14] M. Debiec‐Rychter,et al. Cellular Uptake of the Tyrosine Kinase Inhibitors Imatinib and AMN107 in Gastrointestinal Stromal Tumor Cell Lines , 2006, Pharmacology.
[15] M. Sattler,et al. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). , 2006, Critical reviews in oncology/hematology.
[16] Jooil Kim,et al. Food-Effect Bioavailability and Fed Bioequivalence Studies , 2005 .
[17] V. Fischer,et al. Safety, Pharmacokinetics (PK), Metabolism, and Mass Balance of [14C]-AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl Tyrosine Kinase, in Healthy Subjects. , 2005 .
[18] Donna Neuberg,et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.
[19] A. Racine‐Poon,et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] W. Colburn,et al. Thalidomide Dose Proportionality Assessment following Single Doses to Healthy Subjects , 2001, Journal of clinical pharmacology.
[21] W. L. Chiou,et al. Similarity in the linear and non-linear oral absorption of drugs between human and rat. , 2000, International journal of clinical pharmacology and therapeutics.
[22] Brahma N. Singh,et al. Effects of Food on the Clinical Pharmacokinetics of Anticancer Agents , 2004, Clinical pharmacokinetics.